In Kenya, cervical cancer is the second leading cause of cancer-related deaths and the second most common cancer among women. In January 2019, as part of a strategy for preventing and reducing the burden of cervical cancer, the Kenya Ministry of Health (MOH)—through the National Vaccines and Immunization Programme (NVIP)—began preparations to introduce human papillomavirus (HPV) vaccine within its routine immunization schedule. This document details the facility-based HPV vaccine introduction strategy in Kenya, which involves current strategy close collaboration between the MOH and the Ministry of Education. This document was published by JSI in 2021.
We strive to build lasting relationships to produce better health outcomes for all.
